12 citations
,
January 1998 in “Drug safety” Finasteride helps reduce prostate size and symptoms in BPH but is less effective than terazosin and works best for larger prostates.
September 2014 in “PubMed Central” This review discusses the sexual side effects of medical and surgical treatments for benign prostatic hyperplasia, such as erectile dysfunction and changes in ejaculation, but presents no new clinical findings.
19 citations
,
October 2018 in “PLOS ONE” This study found that 5-alpha-reductase inhibitor monotherapy for symptomatic benign prostatic hyperplasia showed some clinical benefit over placebo but was linked to a higher incidence of sexual side effects.
235 citations
,
September 2004 in “The Journal of urology/The journal of urology” This review discusses the role of dihydrotestosterone in benign prostatic hyperplasia and reports no new results; the authors highlight 5alpha-reductase inhibitors as a well-established treatment option.
March 2024 in “The journal of sexual medicine” This case study observed that in four middle-aged men with ejaculation disorders, therapy with human chorionic gonadotropin (hCG) alone or combined with recombinant follicle-stimulating hormone (rFSH) improved sexual desire, semen volume, and various other symptoms, although some experienced elevated estradiol levels and hair loss.